Home / Research projects / GlaxoSmithKline Biologicals SA (GSK)'s investigational respiratory syncytial virus (RSV) vaccine BIO RSV OA=ADJ (GSK3844766A)
Share
GlaxoSmithKline Biologicals SA (GSK)'s investigational respiratory syncytial virus (RSV) vaccine BIO RSV OA=ADJ (GSK3844766A)
Efficacy study of GSK's investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above.
Project objectives
To demonstrate the efficacy of the RSVPreF3 OA investigational vaccine in the prevention of RSV-confirmed LRTD after at least 1 season in adults ≥ 60 YOA.
Start and end date
2021 - 2024
Project Manager
Raffaele Antonelli Incalzi - Principal Investigator
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
